Company profile
ZENTALIS PHARMACEUTICALS, INC.
NASDAQ:ZNTLBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AZENOSERTIB | phase3 | — | 9 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04854174 | phase1 | completed | 2021-06-13 | 2021-06-30 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | A Food Effect Study of ZN-d5 in Healthy Female Volunteers |
| NCT07546500 | phase3 | recruiting | 2026-04-17 | 2028-05-31 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression |
| NCT05198804 | phase1_2 | completed | 2022-01-27 | 2025-10-15 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer |
| NCT04833582 | phase1 | completed | 2021-08-01 | 2023-08-30 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma |
| NCT04158336 | phase1 | completed | 2019-11-01 | 2025-05-06 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors |
FDA applications (0)
No records yet.